Stock listing
Dusseldorf:NV3P NanoViricides, Inc. Aktie
German listing (Dusseldorf) of NanoViricides, Inc. · home listing NYSE American:NNVC
Follow NanoViricides, Inc. into a list and get an email when it puts out news.
Home listing price · AMEX:NNVC
$1.48 USD +0.18 (+13.8%)
Close on Oct 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, AMEX:NNVC
- Day range
- $1.33 – $1.51 USDOct 20, 2026
- Volume
- 462,076 sharesOct 20, 2026
- Market cap
- $37.78M USDAt the close on Oct 20, 2026 · price × 25.52M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:NNVC · Home | $1.48 USD | +0.18 (+13.8%) | 462,076 | $1.325 | $1.51 | $1.325 | $1.30 | Close on Oct 20, 2026 |
| Frankfurt:NV3P | €1.29 EUR | +0.13 (+11.2%) | — | €1.08 | €1.29 | €1.08 | €1.16 | Close on Oct 20, 2026 |
Daily closes
Last 3 months, Jul 20, 2026 – Oct 20, 2026 · AMEX:NNVC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.48 | +0.18 | +13.8% | $1.325 | $1.51 | $1.325 | 462,076 | |
| $1.30 | -0.08 | -5.8% | $1.37 | $1.39 | $1.30 | 161,722 | |
| $1.38 | +0.01 | +0.7% | $1.36 | $1.40 | $1.344 | 154,846 | |
| $1.37 | +0.06 | +4.6% | $1.30 | $1.40 | $1.30 | 197,954 | |
| $1.31 | -0.01 | -0.8% | $1.32 | $1.34 | $1.29 | 150,161 | |
| $1.32 | +0.04 | +3.1% | $1.244 | $1.34 | $1.244 | 237,423 | |
| $1.28 | -0.02 | -1.5% | $1.31 | $1.33 | $1.27 | 132,900 | |
| $1.30 | -0.01 | -0.8% | $1.33 | $1.40 | $1.30 | 169,500 | |
| $1.31 | -0.13 | -9.0% | $1.38 | $1.42 | $1.30 | 298,600 | |
| $1.44 | +0.04 | +2.9% | $1.43 | $1.50 | $1.40 | 305,900 | |
| $1.40 | -0.05 | -3.4% | $1.45 | $1.48 | $1.36 | 301,900 | |
| $1.45 | +0.17 | +13.3% | $1.29 | $1.50 | $1.28 | 704,400 | |
| $1.28 | +0.02 | +1.6% | $1.25 | $1.30 | $1.23 | 239,500 | |
| $1.26 | -0.04 | -3.1% | $1.30 | $1.30 | $1.25 | 205,100 | |
| $1.30 | 0.00 | 0.0% | $1.36 | $1.41 | $1.26 | 425,000 | |
| $1.30 | -0.20 | -13.3% | $1.52 | $1.56 | $1.28 | 968,200 | |
| $1.50 | +0.06 | +4.2% | $1.44 | $1.53 | $1.40 | 632,700 | |
| $1.44 | 0.00 | 0.0% | $1.44 | $1.49 | $1.43 | 413,000 | |
| $1.44 | -0.07 | -4.6% | $1.50 | $1.55 | $1.42 | 461,600 | |
| $1.51 | -0.02 | -1.3% | $1.62 | $1.64 | $1.51 | 316,100 | |
| $1.53 | -0.16 | -9.5% | $1.70 | $1.77 | $1.52 | 1,289,600 | |
| $1.69 | +0.27 | +19.0% | $1.50 | $1.78 | $1.49 | 1,684,000 | |
| $1.42 | +0.02 | +1.4% | $1.40 | $1.48 | $1.36 | 693,400 | |
| $1.40 | +0.20 | +16.7% | $1.30 | $1.42 | $1.25 | 1,460,300 | |
| $1.20 | +0.15 | +14.3% | $1.08 | $1.22 | $1.06 | 1,309,000 | |
| $1.05 | 0.00 | 0.0% | $1.07 | $1.11 | $1.00 | 751,700 | |
| $1.05 | +0.03 | +2.9% | $1.07 | $1.12 | $1.03 | 650,200 | |
| $1.02 | 0.00 | 0.0% | $1.02 | $1.04 | $1.00 | 286,100 | |
| $1.02 | -0.02 | -1.9% | $1.05 | $1.05 | $1.00 | 582,700 | |
| $1.04 | -0.04 | -3.7% | $1.08 | $1.11 | $1.03 | 418,800 | |
| $1.08 | -0.04 | -3.6% | $1.11 | $1.13 | $1.08 | 264,400 | |
| $1.12 | -0.03 | -2.6% | $1.15 | $1.17 | $1.10 | 487,500 | |
| $1.15 | -0.02 | -1.7% | $1.15 | $1.19 | $1.14 | 301,900 | |
| $1.17 | -0.04 | -3.3% | $1.24 | $1.28 | $1.16 | 500,700 | |
| $1.21 | -0.04 | -3.2% | $1.24 | $1.25 | $1.21 | 203,800 | |
| $1.25 | +0.01 | +0.8% | $1.29 | $1.33 | $1.24 | 397,800 | |
| $1.24 | -0.04 | -3.1% | $1.26 | $1.28 | $1.22 | 188,000 | |
| $1.28 | 0.00 | 0.0% | $1.27 | $1.29 | $1.26 | 236,600 | |
| $1.28 | -0.01 | -0.8% | $1.29 | $1.32 | $1.27 | 180,100 | |
| $1.29 | +0.02 | +1.6% | $1.28 | $1.33 | $1.28 | 237,700 | |
| $1.27 | -0.06 | -4.5% | $1.31 | $1.31 | $1.26 | 250,600 | |
| $1.33 | +0.02 | +1.5% | $1.33 | $1.39 | $1.31 | 250,200 | |
| $1.31 | -0.03 | -2.2% | $1.33 | $1.37 | $1.30 | 204,300 | |
| $1.34 | -0.01 | -0.7% | $1.35 | $1.39 | $1.34 | 332,700 | |
| $1.35 | -0.01 | -0.7% | $1.35 | $1.38 | $1.32 | 265,800 | |
| $1.36 | -0.02 | -1.4% | $1.35 | $1.41 | $1.35 | 335,300 | |
| $1.38 | +0.02 | +1.5% | $1.37 | $1.40 | $1.35 | 205,500 | |
| $1.36 | -0.01 | -0.7% | $1.38 | $1.40 | $1.34 | 194,200 | |
| $1.37 | +0.01 | +0.7% | $1.41 | $1.43 | $1.35 | 241,700 | |
| $1.36 | -0.04 | -2.9% | $1.39 | $1.42 | $1.34 | 249,600 | |
| $1.40 | -0.02 | -1.4% | $1.31 | $1.51 | $1.31 | 800,800 | |
| $1.42 | +0.02 | +1.4% | $1.42 | $1.45 | $1.39 | 126,800 | |
| $1.40 | -0.03 | -2.1% | $1.40 | $1.45 | $1.37 | 232,600 | |
| $1.43 | -0.09 | -5.9% | $1.51 | $1.53 | $1.43 | 246,000 | |
| $1.52 | -0.03 | -1.9% | $1.54 | $1.56 | $1.50 | 297,000 | |
| $1.55 | +0.03 | +2.0% | $1.64 | $1.67 | $1.51 | 510,800 | |
| $1.52 | -0.03 | -1.9% | $1.52 | $1.60 | $1.51 | 132,900 | |
| $1.55 | +0.01 | +0.6% | $1.53 | $1.59 | $1.53 | 173,000 | |
| $1.54 | -0.07 | -4.3% | $1.62 | $1.62 | $1.52 | 169,200 | |
| $1.61 | +0.07 | +4.5% | $1.45 | $1.65 | $1.45 | 623,600 | |
| $1.54 | +0.06 | +4.1% | $1.51 | $1.65 | $1.51 | 467,200 | |
| $1.48 | -0.05 | -3.3% | $1.50 | $1.58 | $1.47 | 314,400 | |
| $1.53 | +0.01 | +0.7% | $1.53 | $1.61 | $1.51 | 313,500 | |
| $1.52 | -0.08 | -5.0% | $1.54 | $1.60 | $1.48 | 595,300 | |
| $1.60 | -0.15 | -8.6% | $1.75 | $1.79 | $1.60 | 353,400 | |
| $1.75 | 0.00 | 0.0% | $1.79 | $1.84 | $1.70 | 432,000 |
- Ticker
- Dusseldorf:NV3P
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Oct 20, 2026
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
Latest deck · Oct 7, 2026
NIBA's 153rd Investment Conference 2026
Conference · 23 slides
Latest news
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
Oct 20, 2026
Closed $1.48 (+13.8%) on Oct 20, 2026
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
Oct 13, 2026
Closed $1.32 (+3.1%) on Oct 13, 2026
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
Sep 15, 2026
Closed $1.05 (0.0%) on Sep 15, 2026
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
Sep 8, 2026
Closed $1.08 (-3.6%) on Sep 8, 2026
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
Aug 18, 2026
Closed $1.35 (-0.7%) on Aug 18, 2026
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Aug 10, 2026
Closed $1.40 (-1.4%) on Aug 10, 2026
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
Jul 22, 2026
Closed $1.52 (-5.0%) on Jul 22, 2026
Decks
NIBA's 153rd Investment Conference 2026
Conference · 23 slides · Oct 7, 2026
Shareholder Meeting (November 2025)
Shareholder meeting · 25 slides · Nov 8, 2025
Investor Presentation (September 2024)
Investor deck · 43 slides · Sep 18, 2024
Investor Presentation (December 2023)
Investor deck · 25 slides · Dec 12, 2023
NanoViricides, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 34 in the last 12 months · 56 in all · newest Oct 20, 2026 · oldest 2025
- Decks
- 7 decks · latest Oct 7, 2026
Where NanoViricides, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:NNVC · Home listing | NYSE American | United States | USD |
| LS Exchange:A2PSNF | LS Exchange | Germany | EUR |
| BOATS:NNVC | BOATS | United States | USD |
| Lang & Schwarz:A2PSNF | Lang & Schwarz | Germany | EUR |
| gettex:NV3P | gettex | Germany | EUR |
| Dusseldorf:NV3P · This page | Dusseldorf | Germany | EUR |
| Frankfurt:NV3P | Frankfurt | Germany | EUR |
| Munich:NV3P | Munich | Germany | EUR |
| Stuttgart:NV3P | Stuttgart | Germany | EUR |
| Tradegate:NV3P | Tradegate | Germany | EUR |
Log in to ask 6ix AI your own questions about NanoViricides, Inc.